UniSuper Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

UniSuper Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,500	Closed	-$318K	–	687
2025 Q1	$318K	Hold	4,500	–	–	﹤0.01%	651
2024 Q4	$296K	Sell	4,500 -2,889	-39%	-$194K	﹤0.01%	646
2024 Q3	$519K	Buy	7,389 +2,889	+64%	+$241K	﹤0.01%	621
2024 Q2	$370K	Buy	4,500 +1,800	+67%	+$150K	﹤0.01%	862
2024 Q1	$236K	Buy	2,700 +1,400	+108%	+$125K	﹤0.01%	913
2023 Q4	$125K	Hold	1,300	–	–	﹤0.01%	623
2023 Q3	$115K	Hold	1,300	–	–	﹤0.01%	560
2023 Q2	$113K	Buy	+1,300	New	+$122K	﹤0.01%	560

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UniSuper Management's BMRN Position: Q2 2025 in Review

UniSuper Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 4,500 shares — an estimated $318K sold.

UniSuper Management first reported a position in BMRN in Q2 2023 and held it in 8 quarters. The position peaked at $519K in Q3 2024. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

UniSuper Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
UniSuper Management sold 4,500 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $318K.
UniSuper Management first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 8 quarters.
UniSuper Management's BioMarin Pharmaceuticals position peaked at $519K in Q3 2024.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on UniSuper Management's 13F filing for Q2 2025, filed 22 Jul 2025.